MRNA Falls 11% In A Single Week: How Does It Compare With Others?
Here is how Moderna (MRNA) stacks up against its peers in size, valuation, growth and margin.
- MRNA’s operating margin of -107.1% is negative, lowest among peers; CVAC has 41.1%.
- MRNA’s revenue growth of -38.8% in the last 12 months is negative, lagging SRPT, ALNY, PFE, CVAC, REGN.
- MRNA’s stock is down 69.7% in last 1 year, and trades at a PE of -3.3; it underperformed ALNY, PFE, CVAC, REGN.
As a quick background, Moderna develops mRNA-based therapeutics and vaccines for infectious diseases, immuno-oncology, rare, cardiovascular, and auto-immune diseases, with 44 programs including 26 clinical trials across seven modalities.
| MRNA | SRPT | ALNY | PFE | CVAC | REGN | |
|---|---|---|---|---|---|---|
| Market Cap ($ Bil) | 9.6 | 1.8 | 58.5 | 141.7 | 1.2 | 61.8 |
| Revenue ($ Bil) | 3.1 | 2.5 | 2.3 | 63.8 | 0.5 | 14.2 |
| PE Ratio | -3.3 | -30.9 | -216.9 | 13.2 | 6.4 | 13.9 |
| LTM Revenue Growth | -38.8% | 64.9% | 17.2% | 13.5% | 675.2% | 5.4% |
| LTM Operating Margin | -107.1% | -0.0% | -4.9% | 26.1% | 41.1% | 27.0% |
| LTM FCF Margin | -114.6% | -18.3% | -3.2% | 19.5% | 38.4% | 25.0% |
| 12M Market Return | -69.7% | -87.0% | 67.6% | -7.8% | 60.2% | -50.8% |
Why does this matter? MRNA just went down -27.1% in a month – peer comparison puts stock performance, valuation, and financials in context – highlighting whether it is truly outperforming, lagging behind, and above all – can this continue? Read Buy or Sell MRNA Stock to see if Moderna is really a falling knife. Sharp dips often come with rebound opportunities – see how the stock has dipped and recovered in the past through MRNA Dip Buyer Analysis lens.
While peer comparison is critical Trefis High Quality Portfolio evaluates much more, and is designed to reduce stock-specific risks while giving upside exposure.
Revenue Growth Comparison
| LTM | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| MRNA | -38.8% | -52.6% | -64.2% | 6.4% |
| SRPT | 64.9% | 53.0% | 33.3% | 32.9% |
| ALNY | 17.2% | 23.0% | 76.2% | 22.9% |
| PFE | 13.5% | 6.8% | -41.1% | 24.5% |
| CVAC | 675.2% | 895.5% | -20.3% | -34.5% |
| REGN | 5.4% | 8.3% | 7.8% | -24.3% |
Operating Margin Comparison
| LTM | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| MRNA | -107.1% | -123.3% | -62.8% | 49.9% |
| SRPT | -0.0% | 11.5% | -21.5% | -57.5% |
| ALNY | -4.9% | -7.9% | -15.4% | -75.7% |
| PFE | 26.1% | 23.5% | 7.4% | 37.7% |
| CVAC | 41.1% | 33.2% | -510.1% | -370.0% |
| REGN | 27.0% | 28.1% | 30.9% | 38.9% |
PE Ratio Comparison
| LTM | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| MRNA | -3.3 | -4.5 | -8.1 | 8.5 |
| SRPT | -30.9 | 55.8 | -16.6 | -16.1 |
| ALNY | -216.9 | -108.0 | -54.3 | -25.6 |
| PFE | 13.2 | 18.7 | 76.7 | 9.2 |
| CVAC | 6.4 | 4.7 | -3.6 | -4.6 |
| REGN | 13.9 | 17.4 | 23.7 | 17.8 |
The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.